NCT04295356View on ClinicalTrials.gov

To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

CT-P17

subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks

BIOLOGICAL

CT-P17

subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04295356 - To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17 | Biotech Hunter | Biotech Hunter